Short-Term Drop in Antibody Titer after the Third Dose of SARS-CoV-2 BNT162b2 Vaccine in Adults

Little is known about the longevity of antibodies after a third dose of the mRNA-based SARS-CoV-2 vaccine BNT162b2 (BioNTech/Pfizer, Mainz, Germany). Therefore, serum antibody levels were evaluated after a third dose of BNT162b2 in healthy adult healthcare workers in Germany. These antibody levels d...

Descripción completa

Detalles Bibliográficos
Autores principales: Herzberg, Jonas, Fischer, Bastian, Becher, Heiko, Becker, Ann-Kristin, Honarpisheh, Human, Guraya, Salman Yousuf, Strate, Tim, Knabbe, Cornelius
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9145913/
https://www.ncbi.nlm.nih.gov/pubmed/35632564
http://dx.doi.org/10.3390/vaccines10050805

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9145913/
https://www.ncbi.nlm.nih.gov/pubmed/35632564
http://dx.doi.org/10.3390/vaccines10050805

Ejemplares similares